OTCMKTS:AVCTF Avacta Group (AVCTF) Stock Forecast, Price & News $1.50 0.00 (0.00%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$1.50▼$1.5050-Day Range$1.25▼$2.0552-Week Range$1.25▼$2.29VolumeN/AAverage Volume1,040 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsHeadlinesShort InterestProfileChartCompetitorsHeadlinesShort Interest About Avacta Group (OTCMKTS:AVCTF) StockAvacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.Read More Receive AVCTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter. Email Address AVCTF Stock News HeadlinesJune 5, 2023 | lse.co.ukAvacta sees shares rise on new equity payment for South Korea ventureJune 1, 2023 | finance.yahoo.comAvacta Group's (LON:AVCT) investors will be pleased with their solid 218% return over the last five yearsJune 5, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 5, 2023 | finance.yahoo.comAvacta Group Plc's (LON:AVCT) Business Is Trailing The Industry But Its Shares Aren'tMay 2, 2023 | americanbankingnews.comAvacta Group Plc (OTCMKTS:AVCTF) Short Interest Down 8.0% in AprilApril 7, 2023 | marketwatch.comAvacta Group's Shares Rise on US Site Openings for Cancer Study Patient EnrolmentApril 6, 2023 | lse.co.ukAvacta doses first patient in fifth cohort of AVA6000 phase 1 studyApril 6, 2023 | lse.co.ukAvacta opens first two clinical investigator sites in US for AVA6000June 5, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!April 5, 2023 | finance.yahoo.comAvacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation StudyApril 1, 2023 | finance.yahoo.comAvacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual MeetingMarch 31, 2023 | finanznachrichten.deAvacta Group plc: Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics DivisionMarch 31, 2023 | finance.yahoo.comAvacta Group Plc (LON:AVCT) is favoured by institutional owners who hold 55% of the companyJanuary 17, 2023 | benzinga.comAvacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical StudyDecember 1, 2022 | finance.yahoo.comInvestors in Avacta Group (LON:AVCT) have made a incredible return of 538% over the past three yearsSeptember 11, 2022 | fool.co.ukAvacta GroupSeptember 5, 2022 | finance.yahoo.comAvacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug AdministrationSeptember 1, 2022 | finance.yahoo.comAvacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth CohortMay 3, 2022 | finance.yahoo.comEven though Avacta Group (LON:AVCT) has lost UK£39m market cap in last 7 days, shareholders are still up 304% over 3 yearsApril 13, 2022 | finance.yahoo.comAvacta Announces AffyXell Joint Venture Milestone and Increased Equity StakeJanuary 18, 2022 | finance.yahoo.comWhat You Need To Know About Avacta Group Plc's (LON:AVCT) Investor CompositionNovember 29, 2021 | finance.yahoo.comAvacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000November 19, 2021 | finance.yahoo.comAvacta Group (LON:AVCT) shareholder returns have been enviable, earning 486% in 3 yearsJuly 1, 2021 | finanznachrichten.deAvacta Group plc: Avacta Announces AffiDX SARS-CoV-2 Antigen Lateral Flow Test Detects Delta VariantJune 29, 2021 | markets.businessinsider.comAvacta : AffiDX Antigen Lateral Flow Test Detects Delta Variant Of SARS-CoV-2 VirusJune 29, 2021 | lse.co.ukAIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbsJune 29, 2021 | finance.yahoo.comAvacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Detects Delta VariantSee More Headlines AVCTF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Miscellaneous Commercial Services Sub-IndustryN/A SectorBusiness Services Current SymbolOTCMKTS:AVCTF CUSIPN/A CIKN/A Webwww.avacta.com Phone44.1904.21.7070FaxN/AEmployees123Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesDr. David Alastair SmithCEO & Exec. DirectorMr. Tony Gardiner (Age 51)CFO, Company Sec. & Exec. Director Comp: $310.25kMs. Emma WrightGroup In-House CounselMr. Michael VinegradGroup Communications DirectorDr. Matt JohnsonChief Scientific Officer of DiagnosticsDr. Neil Bell (Age 64)Chief Devel. Officer of Therapeutics Dr. Fiona McLaughlin FSB (Age 52)Ph.D., Chief Scientific Officer of Therapeutics Division Mr. Marc GreenHead of Product Devel. - DiagnosticsGemma WilsonHead of QA/RA - DiagnosticsMr. Petros SarantosHead of Product Management - DiagnosticsMore ExecutivesKey CompetitorsDKSHOTCMKTS:DKSHFdotdigital GroupOTCMKTS:DOTDFElisOTCMKTS:ELSSFFantexOTCMKTS:EJMLLGDI Integrated Facility ServicesOTCMKTS:GDIFFView All Competitors AVCTF Stock - Frequently Asked Questions How have AVCTF shares performed in 2023? Avacta Group's stock was trading at $1.5799 on January 1st, 2023. Since then, AVCTF stock has decreased by 5.1% and is now trading at $1.50. View the best growth stocks for 2023 here. What is Avacta Group's stock symbol? Avacta Group trades on the OTCMKTS under the ticker symbol "AVCTF." How do I buy shares of Avacta Group? Shares of AVCTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avacta Group's stock price today? One share of AVCTF stock can currently be purchased for approximately $1.50. How many employees does Avacta Group have? The company employs 123 workers across the globe. How can I contact Avacta Group? Avacta Group's mailing address is Thorp Arch Estate, Leeds, West Yorkshire. The official website for the company is www.avacta.com. The company can be reached via phone at 44.1904.21.7070. This page (OTCMKTS:AVCTF) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.